L-756423 + indinavir

**L-756423 + indinavir** is an investigational fixed-dose combination of two **HIV-1 protease inhibitors**. L-756423 is a small molecule inhibitor of HIV-1 protease developed by Merck, while indinavir is a well-characterized HIV protease inhibitor widely used in antiretroviral therapy. The combination was studied as a potential once-daily regimen for HIV, aiming to maintain antiretroviral efficacy and safety, and possibly improve resistance profiles or reduce dosing frequency. Trials evaluated this combination alongside nucleoside reverse transcriptase inhibitors such as stavudine and lamivudine, including in patients who had previously failed indinavir regimens. The clinical development has been suspended and is not marketed[1][2][4][5][7].

Other names

indinavirindinavir sulfate